MCBÜ Açıkerişim Sistemi :: Browsing by Author "Aksoy A."

Browsing by Author "Aksoy A."

Now showing 1 - 20 of 20

XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: A retrospective study of the anatolian society of medical oncology
(Asian Pacific Organization for Cancer Prevention, 2014) Duran A.O.; Karaca H.; Besiroglu M.; Bayoglu I.V.; Menekse S.; Yapici H.S.; Yazilitas D.; Bahceci A.; Uysal M.; Sevinc A.; Hacibekiroglu I.; Aksoy A.; Tanriverdi O.; Arpaci E.; Inanc M.; Dane F.; Ozkan M.
Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC).The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n = 298) received XELOX-Bev and Group 2 (n = 111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%) , stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95%CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95%CI; 16.8-23.1) for Group 2 (p = 0.036). Median PFS was 9.6 months (range 2-36 months, 95%CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95%CI; 7.4-10.5) for Group 2 (p = 0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p < 0.001). Conclusions: First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev.
Adult urological soft tissue sarcomas: A multicenter study of the anatolian society of medical oncology (ASMO)
(Asian Pacific Organization for Cancer Prevention, 2015) Unal O.U.; Oztop I.; Menekse S.; Urakci Z.; Bozkurt O.; Ozcelik M.; Gunaydin Y.; Yasar N.; Yazilitas D.; Kodaz H.; Taskoylu B.Y.; Aksoy A.; Demirci U.; Araz M.; Tonyali O.; Sevinc A.; Yilmaz A.U.; Benekli M.
Objective: To analyze clinicopathological characteristics, prognostic factors and survival rates of the patients with urological soft tissue sarcomas treated and followed up in Turkey. Materials and Methods: For overall survival analyses the Kaplan-Meier method was used. From medical records, nine prognostic factors on overall survival were analysed. Results: For the 53 patients (34 males, 19 females) whose charts were reviewed, the median age was 53 (range 22 to 83) years. Most frequently renal location (n=30; 56.6%) was evident and leiomyosarcoma (n=20, 37.7%) was the most frequently encountered histological type. Median survival time of all patients was 40.3 (95% CI, 14.2-66.3) months. In univariate analysis, male gender, advanced age (=50 years), metastatic stage, unresectability, grade 3, renal location were determined as worse prognostic factors. In multivariate analysis, metastatic stage, unresectability and grade 3 were determined as indicators of worse prognosis. Conclusions: Urological soft tissue sarcomas are rarely seen tumours in adults. The most important factors in survival are surgical resection, stage of the tumour at onset, grade and location of the tumour, gender and age of the patients.
Assessment of sexual function in women with macromastia and their partners
(Ediciones Doyma, S.L., 2015) Üçer O.; Sir E.; Güngör M.; Keçeci Y.; Aksoy A.; Gümüş B.
Objective: To investigate the sexual function in patients with macromastia and their partners. Materials and methods: 48 patients with macromastia and 30 healthy controls and their partners were enrolled in the study. The sexual function of the women and their partners was evaluated by using the Index of Female Sexual Function (IFSF) and International Index of Erectile Function (IIEF), respectively. Results: Mean ages of the patients and controls were respectively, 33.27 ± 5.24 and 32.06 ±. 3.91 (p > 0.05). Mean IFSF scores of the patients and controls were 23.21 ± 3.16 and 27.33 ± 4.94 (p = 0.00), respectively. All of the subscale scores of IFSF in the patient group were significantly lower than in the control group. Mean IIEF scores of the patients' and controls' partners were 60.33 ± 11.46 and 65.25 ± 6.18 (p = 0.04), respectively. Conclusion: In this study, Macromastia was shown to affect sexual function of women and their partners adversely. © 2014 Asociación Española de Andrología, Medicina Sexual y Reproductiva.
Effect of reduction mammaplasty on sexual activity
(Lippincott Williams and Wilkins, 2016) Sir E.; Üçer O.; Güngör M.; Aksoy A.; Keçeci Y.; Gümü B.
Aim: This study aimed to evaluate the effects of reduction mammaplasty operation on sexual functions of the patients with macromastia and of their partners. Materials and Methods: Thirty-nine patients with macromastia and their partners were assessed for their sexual function before and 6 months after reduction mammaplasty. Sexual function of the women and their partners were evaluated using the Index of Female Sexual Function (IFSF) and the International Index of Erectile Function (IIEF), respectively. Controls (n = 33) were chosen from healthy hospital staff and their partners. Preoperative and postoperative scores were statistically compared with the controls' scores by using Student t test. Also, preoperative and postoperative scores were compared by using paired t test. Results: The mean of age and body mass index of the women and their partners in the patient and control group were similar (P = 0.07). Before the operation, the mean of IFSF scores in the patient and control group were 22.75 (3.45) and 27.28 (5.05), respectively (P < 0.001). After the operation, the mean of IFSF scores in the patient group increased significantly to 27.67 (P < 0.001). The postoperative scores of all IFSF subscales except lubrication subscale were higher than the preoperative scores. Although there was no significant difference between preoperative and postoperative IIEF-total scores, postoperative IIEF-erectile function and IIEF-intercourse satisfaction scores were significantly reduced (P < 0.05). Conclusions:We found that macromastia adversely affected female sexual function but reduction mammaplasty eliminated this adverse effect. We also found that the partners' erectile function and intercourse satisfaction reduced after the operation. This reduction may be due to psychological effects. © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Sexual function and hormone profile in young adult men with idiopathic gynecomastia: Comparison with healthy controls
(IOS Press, 2016) Sir E.; Üçer O.; Aksoy A.; Güngör M.; Ceylan Y.
Objectives: To compare sexual function and hormone profile in male patients with gynecomastia with matched controls. MATERIALS-METHODS: Forty-seven male subjects with gynecomastia and thirty healthy controls were enrolled in this study. Serum free T3, free T4, TSH, FSH, prolactin, estradiol, total testosterone, free testosterone, DHEA-SO4, LH and total PSA were measured in the patients and controls. Sexual function of the patients and controls were evaluated using International Index of Erectile Function (IIEF). The hormone values and IIEF scores of the patients were statistically compared with the controls'. RESULTS: The mean of age, body mass index, right and left testicular volume in the patient and control group were similar. The mean FSH and free T3 values of the patients were significantly lower than the controls (p = 0:007 and p = 0:03, respectively). The mean of the other hormone values in the both groups were found to be statistically similar (p > 0:05). The mean ±SD of total IIEF scores in the patient and control group were 60:14 ± 8:78 and 65:24 ± 5:52, respectively (p = 0:007). Although the mean IIEF-erectile function, orgasmic function and intercourse satisfaction scores in the patient group were significantly lower than the control group (p < 0:001, p = 0:004 and p = 0:001, respectively), the mean IIEF-desire score of the patients was significantly higher than the controls (p = 0:002). CONCLUSION: We found that the hormone profiles (except FSH and free T3) of the patients with gynecomastia were similar with the controls. However, gynecomastia adversely affected male sexual function. © 2016-IOS Press and the authors. All rights reserved.
Predictive and prognostic factors in ovarian and uterine carcinosarcomas
(AVES Ibrahim Kara, 2016) Cicin İ.; Özatlı T.; Türkmen E.; Özturk T.; Özçelik M.; Çabuk D.; Gökdurnalı A.; Balvan Ö.; Yıldız Y.; Şeker M.; Özdemir N.; Yapar B.; Tanrıverdi Ö.; Günaydin Y.; Menekşe S.; Öksüzoğlu B.; Aksoy A.; Erdogan B.; Hacıoglu M.B.; Arpaci E.; Sevinç A.
Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive factors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcinosarcomas may benefit more from adjuvant CT. Aims: We aimed to define the prognostic and predictive factors associated with treatment options in ovarian (OCS) and uterine carcinosarcoma (UCS). Study Design: Retrospective cross-sectional study Methods: We retrospectively reviewed the medical records of patients with ovarian and uterine carcinosarcoma from 2000 to 2013, and 127 women were includ ed in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey between 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data obtained from well-kept medical records were included in this study. Stage IV tumours were excluded. The patient records were retrospectively reviewed. Data from 104 patients were evaluated for this study. Results: Age (≥70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic±para aortic lymph node dissection did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adjuvant radiotherapy tended to increase the median OS (p=0.075). However, this tendency was observed in UCS (p=0.08) rather than OCS (p=0.6).Adjuvant chemotherapy had no effect on OS (p=0.15).Adjuvant radiotherapy significantly prolonged the median OS in patients with endometrioid component (p=0.034). A serous/clear cell component was a negative prognostic factor (p=0.035). Patients with serous/clear cell histology for whom adjuvant chemotherapy was applied had significantly longer OS (p=0.019), and there was no beneficial effect of adjuvant radiotherapy (p=0.4). Adjuvant chemotherapy was effective in heterologous tumours (p=0.026). In multivariate analysis, the stage and chemotherapy were prognostic factors for all patients. Age was an independent prognostic factor for UCS. However, serous/clear cell histology and radiotherapy tended to be significant prognostic factors. Conclusion: The primary location, the histological type of sarcomatous and the epithelial component may be predictive factors for the efficacy of chemotherapy or radiotherapy in UCS and OCS. © Trakya University Faculty of Medicine.
Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less
(Lippincott Williams and Wilkins, 2016) Özaslan E.; Karaca H.; Koca S.; Sevinc A.; Hacioglu B.; Özkan M.; Özcelik M.; Duran A.O.; Hacibekiroglu I.; Yildiz Y.; Tanriverdi O.; Menekse S.; Aksoy A.; Bozkurt O.; Urvay S.; Uysal M.; Demir H.; Ciltas A.; Dane F.
The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were more effective in neuroendocrine tumors (NETs) with a Ki-67 index of 20% or less. Patients who received SSA or CTx and had unresectable locally advanced and metastatic NETs with a Ki-67 index of 20% or less were retrospectively selected from 13 centers in the Turkish database between 2000 and 2015. One hundred and sixty-five patients were enrolled. The median age was 56 years and the male-to-female ratio was 1.09. Seventy-four (45%) patients were of grade 1 NET and 91 (55%) were of grade 2. SSA was given to 104 patients, whereas 61 were treated with CTx. The objective response rate after SSA was 15.4%; another 73.1% had stable disease. The objective response rate after CTx was 36.1%, and 40.9% had stable disease (P=0.008). The median PFS in SSA patients was 21 months (95% confidence interval: 12.4-29.6), and 8 months for CTx (95% confidence interval: 5.5-10.6) (P<0.001). There was no significant difference between PFS of receiving SSA and CTx in pancreatic neuroendocrine tumor (PNET) patients; however, the PFS of receiving SSA was longer in non-PNET patients (P<0.001). SSA was better treatment in advanced NET patients with a Ki-67 index of less than 5%, having a primary resected and a performance status of 0 (P<0.05). SSA may be preferred over CTx in advanced NET patients with low-to-intermediate grade. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology
(Springer Science and Business Media B.V., 2016) Ozcelik M.; Seker M.; Eraslan E.; Koca S.; Yazilitas D.; Ercelep O.; Ozaslan E.; Kaya S.; Hacibekiroglu I.; Menekse S.; Aksoy A.; Taskoylu B.Y.; Varol U.; Arpaci E.; Ciltas A.; Oksuzoglu B.; Zengin N.; Gumus M.; Aliustaoglu M.
Most data on prognostic factors for patients with high-grade undifferentiated pleomorphic sarcoma (HGUPS) is obtained from analyses of soft tissue sarcomas. The purpose of this study was to evaluate the clinicopathologic features and their impact on outcomes specifically in patients diagnosed with HGUPS. In this multicenter trial, we retrospectively analyzed 112 patients who were diagnosed and treated at 12 different institutions in Turkey. We collected data concerning the patients, tumor characteristics, and treatment modalities. There were 69 males (61.6 %) and 43 females (38.4 %). Median age was 56 years (19–90). The most common anatomic site of tumor origin was the upper extremity. Pleomorphic variant was the predominant histological subtype. Median tumor size was 8.2 cm (0.6–30 cm). Tumors were mainly deeply seated (57.1 %). Fifty-seven patients (50.9 %) were stage II and the remainder were stage III at the time of diagnosis. Median follow-up was 30 months (2–160). The primary site of distant metastasis was the lung (73.5 %) and the second most common site was the liver (11.7 %). The 5-year overall survival, distant metastasis-free survival, and local recurrence-free survival rates were 56.3, 53.4, and 67.2 %, respectively. Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) performance score of II (p = 0.033), deep tumor location (p = 0.000), and development of distant metastasis (p = 0.004) were negatively correlated with overall survival, and perioperative radiotherapy and negative microscopic margins were significant factors for local control rates (p = 0.000 for each). Deep tumor location (p = 0.003) was the only adverse factor related to distant metastasis-free survival. Deep tumor location, ECOG performance score of II, and development of distant metastasis carry a poor prognostic implication on overall survival. These will aid clinicians in predicting survival and treatment decision. © 2015, International Society of Oncology and BioMarkers (ISOBM).
The effect of the gastrectomy on survival in patients with metastatic gastric cancer: A study of ASMO
(Future Medicine Ltd., 2016) Yazici O.; Özdemir N.; Duran A.O.; Menekşe S.; Nahit Şendur M.A.; Karaca H.; Göksel G.; Arpaci E.; Hacibekiroʇlu I.; Bilgetekin I.; Kaçan T.; Özkan M.; Aksoy S.; Aksoy A.; Çokmert S.; Uysal M.; Elkiran E.T.; Çiçin I.; Büyükberber S.; Zengin N.
Aim: To investigate the role of surgical resection of primary tumor on overall survival (OS) in advanced gastric cancer patients at the time of diagnosis. Patients & methods: The survival rates of metastatic gastric cancer patients whose gastric primary tumor was resected at time of diagnosis were compared with metastatic gastric cancer patients whose primary tumor was nonresected. Results: The median progression-free survival and OS in operated and nonoperated group were 10 versus 6, 14 versus 9 months, respectively (p < 0.001). In multivariate analysis, gastric resection of primary tumor, Eastern Cooperative Oncology Group performance status, second-line chemotherapy had a significant effect on OS (hazard ratio [HR]: 0.52 [95% CI: 0.38-0.71], HR: 0.57 [95% CI: 0.42-0.78], HR: 1.48 [1.09-2.01]; p ≤ 0.001, p = 0.001 and p = 0.012, respectively). Conclusion: Subpopulations of patients with metastatic gastric cancer might benefit from surgical removal of primary tumor. © 2016 Future Medicine Ltd.
Central nervous system metastatic epithelial ovarian cancer. Clinical parameters and prognostic factors: A multicenter study of Anatolian Society of Medical Oncology
(S.O.G. CANADA Inc., 2017) Seber S.; Turkmen E.; Harputoǧlu H.; Yeşil H.; Arpaci E.; Menekse S.; Pilanci K.; Oruç Z.; Taskovlu B.Y.; Gumusay O.; Aksoy A.; Karaagac M.; Ozarslan E.; Yetisyigit T.
Central nervous system (CNS) metastasis is a rare event in the course of late stage epithelial ovarian cancer (EOC); however its incidence is increasing in parallel with prolonged survival of patients. Objective: The authors assessed the clinical parameters and potential prognostic features in patients with CNS metastatic disease. Materials and Methods: Clinical data of the 33 patients from the participating centers were retrospectively collected and analyzed. Median age at the time of CNS metastasis was 57 years. Median time from the diagnosis of primary EOC until CNS metastatic disease was 22 months. Nearly half (45.5%) of the patients had single CNS metastatic lesions and all patients in the study group except two received radiotherapy as palliative treatment. Median overall survival (OS) from the time of CNS metastasis was 15 months (0-66). At univariate analysis only number of brain metastatic lesions (p = 0.001) and presence of extracranial disease (p = 0.004) were strongly associated with OS whereas multimodal treatment, size of metastatic lesions, platinum sensitivity, age, grade, and disease stage at presentation were not. Development of CNS metastasis carries a poor prognosis, however patients with single metastatic lesions and only intracranial metastatic disease can have prolonged survival after appropriate palliative management of their disease.
Evaluation of sexual function in women with labia minora hypertrophy: A preliminary study; [Evaluación de la función sexual en las mujeres con hipertrofia en los labios vaginales menores: un estudio preliminar]
(Ediciones Doyma, S.L., 2018) Sir E.; Güngör M.; Üçer O.; Aksoy A.
Objective: To compare the sexual functions in women with labia minora hypertrophy and age-matched healthy controls. Material and method: 43 patients with labia minora hypertrophy and 30 age-matched healthy controls were enrolled in the present study. The sexual functions of the women were evaluated by using the index of female sexual function (IFSF). Results: Mean ages of the patients and controls were 30.06 ± 7.11 and 31.34 ± 4.12 (p = 0.41), respectively. Mean total IFSF scores of the patients and controls were 24.18 ± 3.24 and 27.53 ± 4.43 (p < 0.05), respectively. The subscale scores of IFSF-lubrication, orgasm, satisfaction and pain in the patient group were significantly lower than in the control group (respectively, p < 0.001, p < 0.05, p < 0.001 and p < 0.05). There was no statistically significant difference between IFSF-arousal scores of the patient and control groups (p = 0.30). The mean IFSF-desire scores of the patient group was higher than the controls (p < 0.001). Labia minora hypertrophy was significantly associated with female sexual dysfunction (odds ratio [OR] = 14.97, 95% confidence interval [Cl] = [3.66–61.21], p < 0.001). Conclusion: This study suggests that patients with labia minora hypertrophy have poorer lubrication, satisfaction, pain, and orgasm scores on the IFSF scale compared to age-matched healthy controls. © 2017 Asociación Española de Andrología, Medicina Sexual y Reproductiva
Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma: A Multicentric Study
(Lippincott Williams and Wilkins, 2021) Yilmaz S.; Demirci N.Y.; Metintas S.; Zamani A.; Karadag M.; Guçlu O.A.; Kabalak P.A.; Yilmaz U.; Ak G.; Kizilgoz D.; Ozturk A.; Yilmaz U.; Batum O.; Kavas M.; Serifoglu I.; Unsal M.; Komurcuoglu B.E.; Cengiz T.I.; Ulubay G.; Ozdemirel T.S.; Ozyurek B.A.; Kavurgacı S.; Alizoroglu D.; Celik P.; Erdogan Y.; In E.; Aksoy A.; Altin S.; Gunluoglu G.; Metintas M.
Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 and September 2018, epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), and c-ros oncogene 1 receptor tyrosine kinase gene (ROS1) alterations, demographic characteristics, asbestos exposure, and asbestos-related radiological findings of 1904 patients with lung adenocarcinoma were recorded. Results: The frequencies of EGFR mutations, ALK, and ROS1 rearrangements were 14.5%, 3.7%, and 0.9%, respectively. The rates of EGFR mutations and ALK rearrangements were more frequent in asbestos exposed non-smokers (48.7% and 9%, respectively). EGFR mutation rate was correlated to female gender and not-smoking, ALK rearrangement rate was correlated to younger age, not-smoking, and a history of asbestos exposure. Conclusions: The higher rate of ALK rearrangements in asbestos-exposed lung adenocarcinoma cases shows that asbestos exposure may most likely cause genetic alterations that drive pulmonary adenocarcinogenesis. Copyright © 2020 American College of Occupational and Environmental Medicine.
Shared Biological Pathways and Processes in Patients with Intellectual Disability: A Multicenter Study
(Georg Thieme Verlag, 2022) Günay Ç.; Aykol D.; Özsoy Ö.; Sönmezler E.; Hanci Y.S.; Kara B.; Akkoyunlu Sünnetçi D.; Cine N.; Deniz A.; Özer T.; Ölçülü C.B.; Yilmaz Ö.; Kanmaz S.; Yilmaz S.; Tekgül H.; Yildiz N.; Acar Arslan E.; Cansu A.; Olgaç Dündar N.; Kusgoz F.; Didinmez E.; Gençpinar P.; Aksu Uzunhan T.; Ertürk B.; Gezdirici A.; Ayaz A.; Ölmez A.; Ayanoǧlu M.; Tosun A.; Topçu Y.; Kiliç B.; Aydin K.; Çaǧlar E.; Ersoy Kosvali Ö.; Okuyaz Ç.; Besen Ş.; Tekin Orgun L.; Erol İ.; Yüksel D.; Sezer A.; Atasoy E.; Toprak Ü.; Güngör S.; Ozgor B.; Karadaǧ M.; Dilber C.; Şahinoǧlu B.; Uyur Yalçin E.; Eldes Hacifazlioglu N.; Yaramiś A.; Edem P.; Gezici Tekin H.; Yilmaz Ü.; Ünalp A.; Turay S.; Biçer D.; Gül Mert G.; Dokurel Çetin İ.; Kirik S.; Öztürk G.; Karal Y.; Sanri A.; Aksoy A.; Polat M.; Özgün N.; Soydemir D.; Sarikaya Uzan G.; Ülker Üstebay D.; Gök A.; Yeśilmen M.C.; Yiś U.; Karakülah G.; Bursali A.; Oktay Y.; Hiz Kurul S.
Background Although the underlying genetic causes of intellectual disability (ID) continue to be rapidly identified, the biological pathways and processes that could be targets for a potential molecular therapy are not yet known. This study aimed to identify ID-related shared pathways and processes utilizing enrichment analyses. Methods In this multicenter study, causative genes of patients with ID were used as input for Disease Ontology (DO), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes enrichment analysis. Results Genetic test results of 720 patients from 27 centers were obtained. Patients with chromosomal deletion/duplication, non-ID genes, novel genes, and results with changes in more than one gene were excluded. A total of 558 patients with 341 different causative genes were included in the study. Pathway-based enrichment analysis of the ID-related genes via ClusterProfiler revealed 18 shared pathways, with lysine degradation and nicotine addiction being the most common. The most common of the 25 overrepresented DO terms was ID. The most frequently overrepresented GO biological process, cellular component, and molecular function terms were regulation of membrane potential, ion channel complex, and voltage-gated ion channel activity/voltage-gated channel activity, respectively. Conclusion Lysine degradation, nicotine addiction, and thyroid hormone signaling pathways are well-suited to be research areas for the discovery of new targeted therapies in ID patients. © 2022 Hippokrates Verlag GmbH. All rights reserved.
Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes
(W.B. Saunders Ltd, 2022) Yılmaz Ü.; Gücüyener K.; Yavuz M.; Öncel İ.; Canpolat M.; Saltık S.; Ünver O.; Çıtak Kurt A.N.; Tosun A.; Yılmaz S.; Özgör B.; Erol İ.; Öztoprak Ü.; Elitez D.A.; Direk M.Ç.; Bodur M.; Teber S.; Anlar B.; Aykol D.; Yıldız E.P.; Yarar C.; Kara B.; Haspolat; İncecik F.; Kutluk G.; Dilber C.; Dundar N.O.; Tan H.; Demir E.; Dursun B.D.; Dilek T.D.; Türkdoğan D.; Yalnızoğlu D.; Akbaş S.; Güleç A.; Yılmaz D.; Ayanoğlu M.; Kanmaz S.; Güngör S.; Öztürk G.; Besen; Haliloğlu G.; Karaca N.B.; Öztürk S.; Yüksel D.; Gürkaş E.; Oktay S.; Serin H.M.; Karadağ M.; Hakkı Akbeyaz İ.; Yiş U.; Polat B.G.; Okan M.S.; Bektaş Ö.; Orgun L.T.; Günbey C.; Per H.; Gültutan P.; Öztürk S.B.; Aksoy E.; Akyüz G.; Tekgül H.; Kürekçi F.; Kurul A.S.H.; Çarman K.B.; Alikılıç D.; Duman Ö.; Kömür M.; Yıldırım M.; Alıcı N.; Gümüş H.; Polat M.; Konuşkan B.; Güngör O.; Mert G.G.; Edizer S.; Mıhçı F.; Öztürk S.T.; Toker R.T.; Arslan M.; Şahin S.; Gencpinar P.; Yıldırım E.; Yüksel E.; Ekici A.; Deniz A.; Yayici Köken Ö.; Okuyaz Ç.; Süt N.Y.; Atasoy E.; Solmaz İ.; Yetkin M.F.; Bilgin N.; Atasever A.K.; Tekin H.G.; Dokurel İ.; Özçelik A.; Aksoy A.; Türköz A.N.; Cavusoglu D.; Özkan M.; Tekin E.; Şahin T.U.; Ünalp A.; Koç H.; Sarıgeçili E.; Sarıtaş S.; Ayça S.; Kayılıoğlu H.; Şenoğlu M.Ç.; Kamaşak T.; Asadova N.; Keskin F.; Karaoğlu P.; İpek R.; Acer H.
Background: The discovery of anti-myelin oligodendrocyte glycoprotein (MOG)-IgG and anti-aquaporin 4 (AQP4)-IgG and the observation on certain patients previously diagnosed with multiple sclerosis (MS) actually have an antibody-mediated disease mandated re-evaluation of pediatric MS series. Aim: To describe the characteristics of recent pediatric MS cases by age groups and compare with the cohort established before 2015. Method: Data of pediatric MS patients diagnosed between 2015 and 2021 were collected from 44 pediatric neurology centers across Türkiye. Clinical and paraclinical features were compared between patients with disease onset before 12 years (earlier onset) and ≥12 years (later onset) as well as between our current (2015–2021) and previous (<2015) cohorts. Results: A total of 634 children (456 girls) were enrolled, 89 (14%) were of earlier onset. The earlier-onset group had lower female/male ratio, more frequent initial diagnosis of acute disseminated encephalomyelitis (ADEM), more frequent brainstem symptoms, longer interval between the first two attacks, less frequent spinal cord involvement on magnetic resonance imaging (MRI), and lower prevalence of cerebrospinal fluid (CSF)-restricted oligoclonal bands (OCBs). The earlier-onset group was less likely to respond to initial disease-modifying treatments. Compared to our previous cohort, the current series had fewer patients with onset <12 years, initial presentation with ADEM-like features, brainstem or cerebellar symptoms, seizures, and spinal lesions on MRI. The female/male ratio, the frequency of sensorial symptoms, and CSF-restricted OCBs were higher than reported in our previous cohort. Conclusion: Pediatric MS starting before 12 years was less common than reported previously, likely due to exclusion of patients with antibody-mediated diseases. The results underline the importance of antibody testing and indicate pediatric MS may be a more homogeneous disorder and more similar to adult-onset MS than previously thought. © 2022 European Paediatric Neurology Society
New Approach for Superthin Anterolateral Thigh Flap Elevation
(Lippincott Williams and Wilkins, 2023) Bali Z.U.; Aksoy A.; Tuluy Y.; Parspanci A.; Keçeci Y.; Yoleri L.
Background Anterolateral thigh (ALT) flaps are widely used for soft tissue reconstructions. They have several advantages, most notably a long pedicle, an appropriate pedicle caliber, low donor site morbidity, and the possibility of 2 teams working simultaneously. However, conventional, thick ALT flaps used for reconstructions of head and neck and lower extremity defects may cause postoperative range of motion limitations and cosmetic problems. The aim of this study was to develop and propose strategies to facilitate the harvest of superthin ALT flaps and minimize technical difficulties. This article provides step-by-step instructions for simple, quick, and reliable dissections of superthin ALT flaps. Methods This study retrospectively analyzed data from 60 free superthin ALT flaps used for soft tissue reconstructions in 56 patients between January 2018 and February 2019. Superthin flaps were elevated just above the superficial Scarpa's fascia using a vertical approach. Results Thirty-eight of the patients were operated on for lower extremity wounds, 16 were for head and neck defects, and 6 were for upper extremity wounds. The mean follow-up period was 7 months. The median hospital stay was 10 days. Total flap loss was observed in 4 cases (6.6%), and partial flap loss was observed in another 4 cases (6.6%). Conclusions The superthin elevated ALT flap is a reliable and effective option for the reconstruction of soft tissue defects. In our vertical approach, the wide field of view of the flap perforator provides easy dissection, making it easier to elevate the superthin ALT flap. © Wolters Kluwer Health, Inc. All rights reserved.
Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study
(Tech Science Press, 2023) Guler O.C.; Oymak E.; Yazici G.; Akagunduz O.O.; Cetinayak O.; Erpolat P.; Aksoy A.; Duzova M.; Yildirim B.A.; Kurt M.; Canyilmaz E.; Yavas G.; Akyurek S.; Oksuz D.C.; Saglam E.K.; Celik O.K.; Ozyar E.; Cengiz M.; Onal C.
The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni-and multivariable analyses. The median age of the entire cohort was 56 years (range: 26–87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received cisplatin-based concurrent chemotherapy. The 2-year OS, PFS, and LRFS rates were 58.8%, 46.9%, and 52.4%, respectively, with a median follow-up duration of 41.6 months. Patients’ performance status, clinical nodal stage, tumor size, and treatment response were significant prognostic factors for OS, PFS, and LRFS in univariate analysis. Non-complete treatment response was an independent predictor for poor OS (HR = 4.41, 95% CI, 2.78–7.00, p < 0.001) and PFS (HR = 4.28, 95% CI, 2.79–6.58, p < 0.001), whereas poor performance score was a predictor for worse LRFS (HR = 1.83, 95% CI, 1.12–2.98, p = 0.02) in multivariable analysis. Fifty-two patients (29.7%) experienced grade II or higher toxicity. In this multicenter study, we demonstrated that definitive CRT is a safe and effective treatment for patients with CEC. Higher radiation doses were found to have no effect on treatment outcomes, but a better response to treatment and a better patient performance status did. © 2023, Tech Science Press. All rights reserved.
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
(Newlands Press Ltd, 2023) Kahraman S.; Erul E.; Seyyar M.; Gumusay O.; Bayram E.; Demirel B.C.; Acar O.; Aksoy S.; Baytemur N.K.; Sahin E.; Cabuk D.; Basaran G.; Paydas S.; Yaren A.; Guven D.C.; Erdogan A.P.; Demirci U.; Yasar A.; Bayoglu İ.V.; Hizal M.; Gulbagci B.; Paksoy N.; Davarci S.E.; Yilmaz F.; Dogan O.; Orhan S.O.; Kayikcioglu E.; Aytac A.; Keskinkilic M.; Mocan E.E.; Unal O.U.; Aydin E.; Yucel H.; Isik D.; Eren O.; Uluc B.O.; Ozcelik M.; Hacibekiroglu I.; Aydiner A.; Demir H.; Oksuzoglu B.; Cilbir E.; Cubukcu E.; Cetin B.; Oktay E.; Erol C.; Okutur S.K.; Yildirim N.; Alkan A.; Selcukbiricik F.; Aksoy A.; Karakas Y.; Ozkanli G.; Duman B.B.; Aydin D.; Dulgar O.; Er M.M.; Teker F.; Yavuzsen T.; Aykan M.B.; Inal A.; Iriagac Y.; Kalkan N.O.; Keser M.; Sakalar T.; Menekse S.; Kut E.; Bilgin B.; Karaoglanoglu M.; Sunar V.; Ozdemir O.; Turhal N.S.; Karadurmus N.; Yalcin B.; Nahit Sendur M.A.
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. © 2023 Future Medicine Ltd.
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
(Springer Science and Business Media Deutschland GmbH, 2023) Gursoy P.; Tatli A.M.; Erdem D.; Goker E.; Celik E.; Demirci N.S.; Sakin A.; Atci M.M.; Bayram E.; Telli T.A.; Bilgin B.; Bilici A.; Akangunduz B.; Balli S.; Demirkazik A.; Selçukbiricik F.; Menekse S.; Cavdar E.; Ozturk A.; Bekmez E.T.; Turhal S.; Kilickap S.; Yildirim H.Ç.; Oyan B.; Aksoy A.; Turkoz F.P.; Kut E.; Katgi N.; Sakalar T.; Akyol M.; Ellez H.İ.; Topcu A.; Erdoğan A.P.; Pilanci K.N.; Hedem E.; Arak H.; Akdeniz N.; Alan Ö.; Yapar B.; Nart D.; Yumuk P.F.
Objectives: To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods: We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study. Results: EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p = 0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p = 0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically different than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p = 0.323). Conclusion: In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
(BioMed Central Ltd, 2024) Kahraman S.; Hizal M.; Demirel B.C.; Guven D.C.; Gumusay O.; Uluc B.O.; Bayram E.; Gulbagci B.; Yasar A.; Davarci S.E.; Mocan E.E.; Acar O.; Isik D.; Aydin E.; Karakas Y.; Ozcelik M.; Keser M.; Okutur S.K.; Eren O.; Menekse S.; Aydin D.; Yilmaz F.; Dogan O.; Ozkanli G.; Yucel H.; Sunar V.; Aykan M.B.; Ozdemir O.; Duman B.B.; Keskinkilic M.; Sakalar T.; Inal A.; Karaoglanoglu M.; Aksoy A.; Er M.M.; Turhal N.S.; Kalkan N.O.; Sendur M.A.N.
Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials. To contribute to the literature, we investigated the real-world efficacy, factors associated with survival and the rates of adverse events (AEs) of the treatment with palbociclib or ribociclib plus ET in the HR+/HER2- MBC patient cohort over the age of 65 for age subgroups. In this retrospective study, 348 patients were divided into subgroups: 65–69 years old, 70–79 years old and 80 years and older. Median PFS (mPFS) for whole group was 18.3 (95% CI,14.3–22.3) months. There was no significant difference in mPFS between age groups (p = 0.75). The estimated median OS (mOS) was 39.5 (95% CI, 24.9–54.1) months and there was no significant difference between age groups (p = 0.15). There was a meaningfull numerical difference that did not reach statistical significance in patients who received CDK4/6i treatment as the first line for MBC. Grade 3–4 AEs were reported in 42.7% for the entire group, and neutropenia was the most common (37.3%). It can be concluded that combination therapy with palbociclib or ribociclib with an ET partner has similar efficacy and is safe among subgroups of older patients diagnosed with HR+/HER2-MBC. © The Author(s) 2024.
Corrigendum to “Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes” [Europ. J. Paediatr. Neurol. 41 (2022) 8–18 doi.org/10.1016/j.ejpn.2022.08.006, (S1090379822001246), (10.1016/j.ejpn.2022.08.006)]
(W.B. Saunders Ltd, 2024) Yılmaz Ü.; Gücüyener K.; Yavuz M.; Ibrahim Oncel; Canpolat M.; Saltık S.; Ünver O.; Çıtak Kurt A.N.; Tosun A.; Yılmaz S.; Özgör B.; Ilknur Erol; Öztoprak Ü.; Elitez D.A.; Çobanoğulları Direk M.; Bodur M.; Teber S.; Anlar B.; Erol İ.; Aykol D.; Direk M.Ç.; Yıldız E.P.; Yarar C.; Kara B.; Haspolat; İncecik F.; Kutluk G.; Dilber C.; Dundar N.O.; Tan H.; Öncel İ.; Demir E.; Dursun B.D.; Dilek T.D.; Türkdoğan D.; Yalnızoğlu D.; Akbaş S.; Güleç A.; Yılmaz D.; Ayanoğlu M.; Kanmaz S.; Güngör S.; Öztürk G.; Besen; Haliloğlu G.; Karaca N.B.; Öztürk S.; Yüksel D.; Gürkaş E.; Oktay S.; Serin H.M.; Karadağ M.; Akbeyaz İ.H.; Yiş U.; Polat B.G.; Okan M.S.; Bektaş Ö.; Orgun L.T.; Günbey C.; Per H.; Gültutan P.; Öztürk S.B.; Aksoy E.; Akyüz G.; Tekgül H.; Kürekçi F.; Hız Kurul A.S.; Çarman K.B.; Alikılıç D.; Duman Ö.; Kömür M.; Yıldırım M.; Alıcı N.; Gümüş H.; Polat M.; Konuşkan B.; Güngör O.; Mert G.G.; Edizer S.; Mıhçı F.; Öztürk S.T.; Toker R.T.; Arslan M.; Şahin S.; Gencpinar P.; Yıldırım E.; Yüksel E.; Ekici A.; Deniz A.; Köken Ö.Y.; Okuyaz Ç.; Süt N.Y.; Atasoy E.; Solmaz İ.; Yetkin M.F.; Bilgin N.; Atasever A.K.; Tekin H.G.; Dokurel İ.; Özçelik A.; Aksoy A.; Türköz A.N.; Cavusoglu D.; Özkan M.; Tekin E.; Şahin T.U.; Ünalp A.; Koç H.; Sarıgeçili E.; Sarıtaş S.; Ayça S.; Kayılıoğlu H.; Şenoğlu M.Ç.; Kamaşak T.; Asadova N.; Keskin F.; Karaoğlu P.; İpek R.; Acer H.
The authors would like to apologise for any inconvenience caused. © 2024 European Paediatric Neurology Society

Browsing by Author "Aksoy A."

Results Per Page

Sort Options